EUCTR2004-002136-25-GB进行中（未招募）不适用
A 52-week extension to a multicenter, randomized, double-blind, active controlled study to compare the effect of 52 weeks treatment with LAF237 50 mg bid to metformin up to 1000 mg bid in drug naïve patients with type 2 diabetes
ovartis Pharmaceuticals UK Ltd0 个研究点目标入组 530 人开始时间: 2005年3月16日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 530
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Written informed consent to participate in the extension study.
- •2.Ability to comply with all study requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Premature discontinuation from the core study.
- •2.Concomitant medical conditions that interfere with the interpretation of study results as defined in the core protocol.
- •3.Failure to comply with the core study protocol.
- •4.Potentially unreliable patients, and those judged by the investigator to be unsuitable for the study.
研究者
相似试验
进行中（未招募）
1 期
A 52-week extension to a multicenter, randomized, double-blind, active controlled study to compare the effect of 52 weeks treatment with LAF237 50 mg bid to metformin up to 1000 mg bid in drug naïve patients with type 2 diabetesType II DiabetesEUCTR2004-002136-25-ESovartis Pharma S.A
进行中（未招募）
1 期
A 50 Week Extension to: A Multicenter, Randomized, Double-Blind Factorial Study of the Co-Administration of MK-0431 and Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control - MK-0431 and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes MellitusType 2 Diabetes MellitusEUCTR2005-000407-34-GBMerck Sharp & Dohme Limited900
进行中（未招募）
不适用
A 28-week extension to a multicenter, randomized, double-blind, active controlled study to compare the effect of 24 weeks treatment with LAF237 50 mg bid to rosiglitazone 8 mg qd in drug naïve patients with type 2 diabetesExtensión de 28 semanas del estudio multicéntrico, aleatorizado, doble ciego, con control activo que compara el efecto de 24 semanas de tratamiento con 50 mg bid de LAF237 frente a 8 mg qd de rosiglitazona en pacientes naive con diabetes Tipo 2.Diabetes Mellitus IIEUCTR2004-002644-10-ESovartis Farmaceutica S.A.660
已完成
Unknown
Efficacy and safety of two hyaluronic acid fillers for the treatment of moderate-to-severe nasolabial folds in a Chinese populatioModerate-to-severe nasolabial folds in Chinese patientsSkin and Connective Tissue DiseasesISRCTN11835676Beijing Tsinghua Chang Gung Hospital339
已完成
不适用
SAFETY AND EFFICACY STUDY OF QVM149 IN ASTHMATIC PATIENTSPER-024-16OVARTIS BIOSCIENSES PERU S.A.,26